1. Home
  2. CTSO vs HBIO Comparison

CTSO vs HBIO Comparison

Compare CTSO & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.37

Market Cap

23.9M

Sector

Health Care

ML Signal

HOLD

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$7.59

Market Cap

26.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTSO
HBIO
Founded
1997
1901
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
23.9M
26.5M
IPO Year
2008
2000

Fundamental Metrics

Financial Performance
Metric
CTSO
HBIO
Price
$0.37
$7.59
Analyst Decision
Buy
Buy
Analyst Count
2
2
Target Price
$5.38
$18.00
AVG Volume (30 Days)
68.3K
18.1K
Earning Date
05-01-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
65.79
N/A
EPS
N/A
N/A
Revenue
$22,503,908.00
$116,176,000.00
Revenue This Year
$10.34
$4.77
Revenue Next Year
$22.41
$8.55
P/E Ratio
N/A
N/A
Revenue Growth
48.53
N/A
52 Week Low
$0.30
$0.38
52 Week High
$1.04
$7.63

Technical Indicators

Market Signals
Indicator
CTSO
HBIO
Relative Strength Index (RSI) 47.36 70.10
Support Level $0.36 $5.91
Resistance Level $0.40 $7.50
Average True Range (ATR) 0.04 0.36
MACD -0.00 0.12
Stochastic Oscillator 58.70 86.73

Price Performance

Historical Comparison
CTSO
HBIO

About CTSO Cytosorbents Corporation

CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: